Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.32 |
| ▸ | KMO | O15229 | 3/20 | 0.31 |
| ▸ | C1R | P00736 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320174 | 0.84 | PSEN1 (0.37) | ACLYPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12116357 | 0.78 | KEAP1 (0.37) | ACLY | |
| SCHEMBL3299723 | 0.76 | ACLY (0.33) | ACLYHSD11B1PTGDR2 | |
| SCHEMBL1318221 | 0.71 | PIK3CA (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3297204 | 0.71 | KEAP1 (0.34) | ACLY | |
| SCHEMBL1110141 | 0.70 | PSEN1 (0.38) | ACLYPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3297379 | 0.68 | NTSR1 (0.32) | — | |
| SCHEMBL3298174 | 0.67 | ACLY (0.33) | ACLYHSD11B1PSEN1PSEN2APH1B | |
| SCHEMBL1319294 | 0.67 | KDM4C (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3300362 | 0.67 | ACLY (0.32) | ACLYPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | ACLY 1173/4885HSD11B1 943/4885PSEN1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.